Late stage clinical development plan for cladribine tablets in the treatment of multiple sclerosis

被引：0
|
作者：
Viglietta, V. [1 ]
Greenberg, S. [1 ]
Mikol, D. [1 ]
Weiner, J. [1 ]
Alteri, E. [1 ]
Chang, P. [1 ]
Krumwieh, D. [1 ]
Musch, B. [1 ]
机构：
[1] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2010年 / 257卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P443
引用
收藏
页码：S143 / S144
页数：2
相关论文
共 50 条
  • [31] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [32] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Michels, Renee Else
    de Fransesco, Maria
    Mahajan, Koshu
    Hengstman, Gerald J. D.
    Schiffers, Krijn M. H.
    Budhia, Sangeeta
    Harty, Gerard
    Krol, Marieke
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 857 - 873
  • [33] Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
    Lobo, C.
    Lee, J.
    Chin, A.
    Lui, S.
    Chen, X.
    Evans, E.
    Phillips, A. L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 192 - 193
  • [34] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria de Fransesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2019, 17 : 857 - 873
  • [35] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Comi, Giancarlo
    Cook, Stuart D.
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony C.
    Viglietta, Vissia
    Greenberg, Steven J.
    JOURNAL OF NEUROLOGY, 2013, 260 (04) : 1136 - 1146
  • [36] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [37] Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
    Moiola, Lucia
    Riva, Agostino
    Nicoletti, Ferdinando
    Uccelli, Antonio
    Salvetti, Marco
    Battistini, Luca
    Furlan, Roberto
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (10) : 1811 - 1815
  • [38] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Giancarlo Comi
    Stuart D. Cook
    Gavin Giovannoni
    Kottil Rammohan
    Peter Rieckmann
    Per Soelberg Sørensen
    Patrick Vermersch
    Anthony C. Hamlett
    Vissia Viglietta
    Steven J. Greenberg
    Journal of Neurology, 2013, 260 : 1136 - 1146
  • [39] The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation
    Leist, Thomas P.
    Vermersch, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2667 - 2676
  • [40] Correlation of the clinical progression with the degree and pattern of atrophy in patients with multiple sclerosis treated cladribine tablets
    Pogoda-Wesolowska, Aleksandra
    Aftyka, Joanna
    Zegadlo, Arkadiusz
    Staszewski, Jacek
    Stepien, Adam
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1252 - 1253
12345